Background. The drug of choice for treatment of Streptococcus pneumoniae infection is generally a penicillin (including amoxicillin). Targeted therapy is, however, rarely used, because results of definitive diagnostic tests for pneumonia are not available for several days. Thus, broad-spectrum antibiotics are used for empirical treatment of pneumonia to cover both typical and atypical pathogens. Our purpose was to assess the usefulness of a strategy of targeted antimicrobial therapy based on the results of a rapid urinary antigen test for S. pneumoniae.
Expectorated sputum is the most common laboratory specimen used for etiological diagnosis of CAP, despite the fact that many studies have documented the relatively poor sensitivity and specificity of sputum culture. In addition, the interpretation of the clinical outcome of sputum cultures is fraught with problems associated with poor-quality specimens, upper-airway contamination, and oropharyngeal colonization [2] [3] [4] [5] . Thus, in typical clinical practice, patients generally receive an empirical, broad-spectrum antibiotic regimen rather than a narrow-spectrum antibiotic regimen for targeted individualized therapy.
A new rapid test for diagnosis of pneumococcal Subscription Information for:
pneumonia, the urinary antigen test for Streptococcus pneumoniae (Binax), is now commercially available. Its sensitivity and specificity are superior to those of sputum culture, and it is more sensitive than blood culture [3] [4] [5] . Its sensitivity is also independent of the severity of pneumonia [6] . Therefore, we initiated a prospective, interventional study to assess whether application of the urinary antigen test may allow targeted therapy for CAP at the time of initiation of antibiotic therapy.
METHODS
The Field Military Medical Unit (Korov, Vladmir Region, Russia) has 60 beds in the internal medicine department and is staffed by 3 physicians and 12 nurses. Patients with CAP are placed in this unit and are observed until they are ready to return to their duties. Gram stains, sputum cultures, serologic tests (as described below), complete blood cell counts (CBCs), and chest radiographs were available for all patients. The most common diagnosis for patients in this unit is CAP. Male patients aged 18-24 years were admitted to the study from a military training camp.
Definitions. CAP was defined as radiological evidence of an infiltrate and at least 1 of the following symptoms: fever (temperature, у37.5ЊC), new onset of cough, sputum production, dyspnea and/or tachypnea (breath rate, 120 breaths/min), pleuritic pain, and auscultatory findings, including rales and/ or rhonchi consistent with pulmonary consolidation. Chest radiographs were initially examined by the admitting physicians, and the findings were subsequently confirmed independently by radiologists. The Pneumonia Severity Index (PSI) was used to classify the severity of illness [7] . Because blood urea nitrogen and arterial gas studies were not available, a score of 0 was entered for these parameters. A PSI of 40 was used to define pneumonia of mild severity, and a PSI of 70 was used to define pneumonia of moderate severity.
Study design. This was a prospective, open-labeled, controlled study. The urinary antigen test result for S. pneumoniae was used to classify treatment regimens into 2 groups (figure 1). If the test result was positive, 1000 mg of amoxicillin (Hiconcil; KRKA) was administered orally 3 times per day for 5-10 days. If the test result was negative, 500 mg of clarithromycin (Fromilid; KRKA) was administered orally 2 times per day for 5-10 days.
Patients were excluded from the study if they had a history of hypersensitivity to macrolides or penicillins, suspected aspiration pneumonia, or severe infection requiring parenteral therapy or if they had been hospitalized for 148 h before the onset of pneumonia or had previously received 11 dose of an antibiotic with in vitro activity against S. pneumoniae. Patients who met the inclusion criteria were given oral antibiotics for at least 5 days. Patients were evaluated at the time of enrollment in the study (visit 0) and after days 3-4 (visit 1), 10-12 (visit 2), 17-21 (visit 3), and 31-45 (visit 4) of treatment. Patients received oral hydration as needed; intravenous fluids were not given. This study was approved by the local institutional review board.
Microbiology. Urine samples were collected at visit 0 for detection of pneumococcal antigen by immunochromatography (BinaxNOW test; Binax). Expectorated sputum specimens were collected for Gram stain and bacteriological culture. Only samples that contained !10 squamous epithelial cells and 125 leukocytes per low-power field were considered to be acceptable for interpretation of the Gram stain [8] . Blood cultures were not performed. Blood samples were obtained for a solid-phase EIA (Thermobiolabsystems OY) for IgG and IgM for Mycoplasma pneumoniae and Chalmydophila (Chlamydia) pneumoniae. Serum samples were collected at visits 0, 3, and 4 and were stored at Ϫ70ЊC. In vitro susceptibility testing for S. pneumoniae was performed for penicillin, amoxicillin, erythromycin, clarithromycin, levofloxacin, trimethoprim-sulfamethoxazole (TMP-SMZ), and tetracycline with the broth microdilution method, in accordance with NCCLS criteria.
S. pneumoniae was determined to be the etiology of CAP on the basis of the following criteria: for a definitive diagnosis, a urinary antigen test positive for S. pneumoniae plus growth of S. pneumoniae on sputum culture and/or a sputum Gram stain revealing gram-positive diplococci; for a probable diagnosis, a positive urinary antigen test result or gram-positive diplococci on a sputum Gram stain plus S. pneumoniae growth on sputum culture; for a possible diagnosis, growth of S. pneumoniae on sputum culture or gram-positive diplococci on a sputum Gram stain; and for an unknown diagnosis, commensal flora isolated from respiratory tract cultures, light growth of multiple organisms on culture, or a Gram stain revealing the presence of multiple organisms.
M. pneumoniae and C. pneumoniae were designated as the etiology on the basis of the following serologic criteria: (1) a single elevated IgM titer of 11.1:1, or (2) seroconversion, as defined by an increase in the IgG titer of 1.3 or 1.5 for convalescent-phase serum samples when the titer of the acutephase serum sample was у130 EIU or !130 EIU, respectively.
Analysis of efficacy. Efficacy or failure of treatment was assessed by the investigator in accordance with Infectious Diseases Society of America guidelines on clinical trials of antiinfective drugs (i.e., insufficient lessening of signs and symptoms of infection, such that additional or alternative antimicrobial therapy was required) [9] . Early treatment failures (at visits 1-2) were classified as failures at both visit 3 and visit 4, and treatment failures at visit 3 were also considered to be failures at visit 4. Efficacy was defined as resolution or improvement of acute signs and symptoms related to pneumonia, Figure 1 . Efficacy of treatment, classified by antibiotic administered. *Of the 28 patients with negative urinary antigen test results, Streptococcus pneumoniae was diagnosed by sputum culture and/or Gram stain. Thirteen patients were coinfected with atypical pathogens, as determined by serologic testing; the efficacy rate for clarithromycin in this subgroup was 92% (12 of 13 patients) ( as well as a decrease or resolution of pulmonary infiltrates. Failure was defined as persistence or worsening of signs and symptoms of pneumonia after 72-96 h and/or appearance of new symptoms that required administration of new or additional antimicrobials, as well as infiltrates seen on chest radiographs progressing after 72-96 h or appearance of new infiltrates consistent with pneumonia.
Statistical analysis. Statistical analyses were performed with SAS software, version 8.2 (SAS Institute). The primary efficacy variable was the clinical response at visit 4 (i.e., the late follow-up visit). For comparison of ordered categories, MantelHaenszel correlation tests were used. For unordered categories, Fisher's exact test was used. Significance was defined as P ! on a 2-sided test. .05
RESULTS

Patients
A total of 220 patients were enrolled in the study. One patient was withdrawn from the study during the first 48 h because of a violation of inclusion criteria, leaving 219 patients evaluable for efficacy analyses. Patients had a significantly higher severity of pneumonia, as defined by the PSI, if the urinary antigen test result was positive ( ) (table 1) . Patients were P ! .05 also significantly more likely to have signs of more-severe pneumonia, as assessed by symptoms, vital signs, and physical examination, if the urinary antigen test result was positive (P ! ) (table 2) . .05
Etiology
Ninety-eight (44.7%) of the 219 patients provided sputum samples. Of these, 73 (75%) fulfilled the Murray-Washington Class V criteria [8] . In 37 (51%) of 73 cases, gram-positive diplococci were the predominant microorganisms on Gram stain. S. pneumoniae was classified as the etiology in 76 patients (35%) (tables 3 and 4). One hundred fifty-two patients underwent serologic testing for C. pneumoniae and M. pneumoniae. Atypical pathogens were classified as etiologic agents of pneumonia in 71 patients (32%); 47 (21%) of 219 patients were infected with C. pneumoniae and/or M. pneumoniae, and 24 (11%) were coinfected by an atypical pathogen plus S. pneumoniae (table 4) .
Antibiotic Therapy
One hundred seventy-one (78%) of 219 patients received clarithromycin because they had urinary antigen tests that were negative for S. pneumoniae, and 48 (22%) received amoxicillin because they had positive urinary antigen test results (figure Antimicrobial susceptibility was determined for 24 S. pneumoniae isolates. All 24 isolates were susceptible to all but 2 antibacterial agents tested; 83% were resistant in vitro to TMP-SMZ, and 38% were resistant in vitro to tetracycline. All were susceptible to penicillins, cephalosporins, macrolides, and quinolones.
Efficacy of Therapy
Therapy was defined as efficacious for 161 (94%) of 171 patients who were treated with clarithromycin and for 43 (90%) of 48 who were treated with amoxicillin ( significant [NS]). P p not All patients who were classified as having had treatment failure were ultimately successfully treated with other antibiotics for prolonged durations. No patients died in either treatment group.
Of the 48 patients in the pneumococcal pneumonia group with a positive urinary antigen test result, therapy was effective for 43 (90%). Twenty-eight patients with pneumococcal pneumonia who had negative urinary antigen test results but who received a diagnosis of S. pneumoniae pneumonia (on the basis of sputum culture and/or Gram stain) received clarithromycin, as per the study protocol; the efficacy rate was 96% (27 of 28 patients) (table 5 and figure 1 ). When this group was subclassified further by criteria for diagnosis of S. pneumoniae pneumonia, the efficacy rate was 100% (8 of 8 patients) for patients classified as having probable S. pneumoniae pneumonia and 95% (19 of 20) for those classified as having possible S. pneumoniae pneumonia. Eleven patients who had positive urine antigen test results but who had evidence of atypical infection (by serologic criteria) were treated with amoxicillin; the efficacy rate was 82% (9 of 11 patients) (table 5 and figure 1 ).
In the patients who had pneumonia due to atypical pathogens with no coinfection with S. pneumoniae, the efficacy rate for clarithromycin was 89% (36 of 38 patients); the rates were 67% (6 of 9) for M. pneumoniae alone, 100% (27 of 27) for C. pneumoniae alone, and 82% (9 of 11) for coinfection with both C. pneumoniae and M. pneumoniae (table 5). In the patients for whom the etiology was unknown, the rate of efficacy for clarithromycin was 96% (92 of 96 patients).
In 152 patients for whom both serologic tests for atypical pathogens and S. pneumoniae tests were performed (i.e., excluding patients for whom serologic tests were not performed), the efficacy rates were 92% (24 of 26) for amoxicillin and 94% (118 of 126) for clarithromycin.
Severity of illness. Patients who had positive urinary antigen test results (i.e., the amoxicillin group) had significantly more-severe disease than did patients with negative urinary antigen test results (i.e., the clarithromycin group; ) P ! .005 (table 1). The efficacy rates for clarithromycin therapy for patients classified as having mild and moderate pneumonia (PSI of 40 and 70, respectively) were 96% (117 of 122 patients) and 90% (44 of 49), respectively. Similarly, the efficacy rates for amoxicillin for patients with mild and moderate pneumonia were 86% (19 of 22 patients) and 92% (24 of 36), respectively ( ). However, the PSI is not an ideal measurement of P p NS severity of illness; when the Curb65 score [10] and a modification of the Pitt bacteremia score [11] were used in place of the PSI score, the results were unchanged (i.e., patients with more-severe illness were in the positive urinary antigen test result group; data not shown).
Response of clinical manifestations. Fever resolved by day 3 in 41 (85%) of 48 patients in the amoxicillin group and in 153 (89%) of 171 patients in the clarithromycin group (P p ). However, other clinical manifestations resolved more rap-NS idly in patients who had negative urine antigen test results (figure 2); this difference was statistically significant for cough, sputum, and chills. Rhinitis resolved significantly more slowly among patients with negative urinary antigen test results than among those with positive results (data not shown).
DISCUSSION
S. pneumonia is not only the most common bacterial cause of CAP, but it is also the most frequent cause of CAP-related death. Both quinolone and macrolide resistance are now emerging for S. pneumoniae.
A urinary antigen test for S. pneumoniae is now commercially available. With the availability of this sensitive and presumably specific test, which is rapid (results are available within minutes), easy to perform, and inexpensive, the possibility of targeted antibiotic therapy for S. pneumoniae now exists. Therefore, we used this urinary antigen test as the key test for decision-making regarding the selection of antibiotic therapy for immunocompetent patients with nonsevere pneumonia. If the urinary antigen test was positive for S. pneumoniae, an oral blactam agent (amoxicillin) was administered. If the urinary antigen test result was negative, an oral macrolide (clarithromycin) was administered. The latter selection is consistent with consensus guidelines for empirical antibiotic therapy for CAP from both the American Thoracic Society [12] and the Infectious Diseases Society of America, and these guidelines are based, in part, on local susceptibility data [13] .
The etiology of nonsevere CAP in the military trainees in our study was primarily S. pneumoniae, followed by atypical pathogens (table 4), which is similar to the results of other studies [8, [14] [15] [16] [17] [18] [19] [20] [21] [22] . Both clarithromycin and amoxicillin proved to be efficacious. The rates of efficacy were 94% (161 of 171 patients) for clarithromycin and 90% (43 of 48) for amoxicillin ( ). For the subgroup of 28 patients classified as having P p NS S. pneumoniae pneumonia who received clarithromycin, the rate of efficacy for clarithromycin was 96% (26 of 27 patients), which is similar to that for amoxicillin (43 [90%] of 48; ) (table 5 and figure 1 ). Eleven patients with urinary P p NS antigen tests positive for S. pneumoniae had coinfection with atypical pathogens, as determined by serologic criteria; 9 (82%) of these 11 patients were cured with amoxicillin alone. Of all patients classified as having treatment failure, none died. All were successfully treated with antibiotics other than the study antibiotics for prolonged duration.
It should be noted that patients who were allocated to the amoxicillin group were more severely ill before antibiotic administration. Specifically, the severity of illness (as defined by the PSI), abnormal vital signs, and abnormal lung findings at study admission occurred more frequently in the positive urinary antigen test result group (i.e., the amoxicillin group) (tables 1 and 2). No significant difference in treatment efficacy was seen when stratified by etiology (table 5) and severity of pneumonia.
Interestingly, studies from the 1920s to the 1990s showed that S. pneumoniae caused a majority of cases of CAP [23] [24] [25] [26] . However, in more recent studies, S. pneumoniae, while remaining the most common etiology, has accounted for !50% of cases of CAP. One suggested reason for the decrease in the incidence of pneumococcal pneumonia and the increase in the incidence of pneumonia of uncertainty etiology is the lack of emphasis on Gram stains and on obtaining adequate sputum samples [27, 28] . This hypothesis is supported by a 1999 study of the lung aspirate specimens of 55 patients in whom no microbial cause could be identified by conventional microbiologic testing; S. pneumoniae was the most common etiology [29] . It is important to note that, in our study, the urine antigen test was the only diagnostic test positive for S. pneumoniae for 32 patients. Had this test not been available, these patients would have otherwise received diagnoses of pneumonia due to atypical pathogens or pneumonia of unknown etiology. According to current guidelines, these patients would have received broad-spectrum antibiotic therapy, such as therapy with a third-generation cephalosporin, a quinolone, or a macrolide. However, our study documented that these patients fared just as well receiving a penicillin.
Our study has a number of limitations. It was performed with military trainees who were young (mean age, 19 years) and were generally healthy, with no underlying diseases, so these results cannot necessarily be extrapolated to other populations.
A second limitation was the application of serologic test results as the sole criterion for designation of atypical pathogens as etiologic agents for CAP; however, the only modalities currently available to the clinician are serologic tests. There is no gold standard for the diagnosis of M. pneumoniae or C. pneumoniae pneumonia, and thus, the specificity of serologic testing is uncertain [30] . Complete serologic testing data for C. pneumoniae and M. pneumoniae were evaluable only for 152 (69%) of 219 patients, because convalescent-phase serum samples were often not obtainable from soldiers discharged from the medical unit. A third limitation was that Legionella microbiology testing was not performed; however, the incidence of Legionella infection is very low for immunocompetent patients treated for "ambulatory" pneumonia [31] . A fourth limitation was that viral studies were not performed. Thus, the rate of CAP due to these pathogens was probably underestimated. Interestingly, S. pneumoniae has been found to be a major cause of pneumonia in children thought to have viral pneumonia [32] . A fifth limitation was that, for 96 (44%) of 219 patients, an etiology could not be determined. (This trend of observational studies of CAP in which the etiology cannot be determined is a focus of an insightful editorial that bemoans the decline in quality of microbiology [27] .)
S. pneumoniae was uniformly active in vitro for the study antibiotics, clarithromycin and amoxicillin. No isolates were found to be resistant to penicillin, as defined by NCCLS criteria, but high-level in vitro resistance was seen for TMP-SMZ and tetracycline. These data are similar to those previously published in in vitro studies of S. pneumoniae isolated from Russian patients [33] . Thus, it may be claimed that our targeted approach may not be possible in geographic areas where highlevel penicillin resistance exists for S. pneumoniae. We point out, however, that numerous studies have documented that penicillin resistance, as defined by NCCLS criteria, has little impact on clinical outcome, even when discordant antibiotic therapy is administered [34] [35] [36] [37] .
We found the routine application of urinary antigen for S. pneumoniae in patients with CAP to be useful in at least 2 ways:
1. The results of the urinary antigen test identified patients who were more severely ill (tables 1 and 2). Although the efficacy rate was similar for both urinary antigen-positive and urinary antigen-negative patients, the clinical response was slower for urinary antigen-positive patients (figure 2). Pneumococcal pneumonia is known to be more severe than pneumonia due to C. pneumoniae and M. pneumoniae and to have a notably higher mortality rate [25, 38] . Thus, the urinary antigen test can be used to identify patients who need moreextensive monitoring and follow-up.
2. Most importantly, the positive results of the urinary antigen test allowed us to administer targeted therapy with an antibiotic of the penicillin class (amoxicillin) rather than broader-spectrum antibiotic therapy (e.g., treatment with a quinolone or a macrolide). The cost of amoxicillin was notably lower than that of clarithromycin. Thus, broad-spectrum agents, such as macrolides or quinolones, can be reserved for patients whose urinary antigen tests are negative for S. pneumoniae. Additional trials of this approach in other patient populations and other clinical settings are warranted.
